For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ Elamipretide
Illustration for Elamipretide

THE PEPSRADAR ENCYCLOPEDIA

Elamipretide

Mitochondrial-targeted peptide

Prescription medicines · Sources checked 2026-10-04

Read the studies ↓Explore the molecule ↗

Elamipretide · KEY FACTS

Content updated · how dates work

Saved peptides

Compare: MOTS-c vs Elamipretide

What is Elamipretide?

Elamipretide targets mitochondrial biology. Its approved product, Forzinity, has a specific Barth syndrome indication rather than a general anti-aging use.

Biological role or research focus

Mitochondrial-targeted peptide.

Forzinity has a specific Barth syndrome indication; this is not approval for general longevity use.

Role reference: A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. ↗

Names you may encounter

SS-31 · SS31 · Forzinity

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity
Mitochondrial-targeted tetrapeptide
Main research area
Barth syndrome
Evidence featured
Human crossover trial + open extension
Source check
October 4, 2026

Source: A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. ↗

Quick answers

Is Elamipretide FDA approved?
Yes. Forzinity (NDA 215244, accelerated approval September 19, 2025) to improve muscle strength in patients with Barth syndrome weighing at least 30 kg. Source ↗
Is Elamipretide safe?
Recently approved mitochondria-targeting drug for Barth syndrome; human safety data are very limited, and injection-site and allergic reactions are the main concerns. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
Is Elamipretide banned in sport?
It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗
Has the FDA taken action over Elamipretide?
Yes. Our records list 2 FDA actions naming it, most recently on August 24, 2026: FDA warning letter to a "research peptide" seller (Peak Performance Peptides) naming "SS-31" (elamipretide), "PT-141", tesamorelin and GLP-1 products as unapproved new drugs. Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

1 Human research1 Animal / mixed laboratory research
StudyTypePopulation / model
TAZPOWER (2021)Human crossover trial + open extension12 participants with Barth syndrome in the blinded phase.
SS-31 · inflammatory memory model (2019)Animal studyMice with lipopolysaccharide-induced inflammation and memory impairment.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Human crossover trial + open extension · 2021

TAZPOWER

A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism.

Population / model
12 participants with Barth syndrome in the blinded phase.
Study design
12-week crossover periods with washout, then an open-label extension.
Main finding
Neither primary endpoint—six-minute walking distance or symptom score—was met in the blinded phase. Improvements appeared in the extension, with eight participants reaching 36 weeks.
Limits & context
An uncontrolled extension is less reliable for attributing benefit. Read the later FDA decision separately: accelerated approval used knee-muscle strength and requires confirmation of clinical benefit.

Source: A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. ↗

Animal study · 2019

SS-31 · inflammatory memory model

What does the mouse cognition experiment establish?

Population / model
Mice with lipopolysaccharide-induced inflammation and memory impairment.
Study design
Behavioral testing plus hippocampal mitochondrial, inflammatory, cell-death, and synaptic measurements.
Main finding
Elamipretide improved the tested learning and memory outcomes alongside mitochondrial and synaptic measures.
How to read it
Improvement after experimentally induced inflammation is distinct from preventing dementia or improving normal human memory.
Limits & context
The abstract does not provide group sizes or numerical treatment effects. Animal findings cannot establish perioperative cognitive benefit or safety in humans.

Source: Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice. ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

20 registered studies name Elamipretide as an intervention; 3 are recruiting or under way, 1 has not started recruiting yet, 13 completed and 3 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.

StudyStatusPhaseStartPeople
Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Subcutaneous Injections of Elamipretide in Pediatric Subjects With Barth Syndrome
NCT07927972 · Stealth BioTherapeutics Inc.
Not yet recruitingPhase 12026-116
Clinical Trial in Patients With Barth Syndrome- 4TAZPower
NCT07531251 · Stealth BioTherapeutics Inc.
RecruitingPhase 42026-07-0248
An Intermediate Size Expanded Access Protocol of Elamipretide
NCT04689360 · Stealth BioTherapeutics Inc.
AVAILABLE
ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)
NCT06373731 · Stealth BioTherapeutics Inc.
Active, not recruitingPhase 32024-05-30313
FRDA Investigator Initiated Study (IIS) With Elamipretide
NCT05168774 · Children's Hospital of Philadelphia
CompletedPhase 1 / Phase 22022-03-0320
Study of Healthy Aging and Physical Function With Elamipretide
NCT07275424 · David Marcinek
RecruitingPhase 22025-11-2630
Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)
NCT05162768 · Stealth BioTherapeutics Inc.
CompletedPhase 32022-04-29102
ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA
NCT03891875 · Stealth BioTherapeutics Inc.
CompletedPhase 22019-03-27176

A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 20 listed studies.

Further reading · 3 additional publication links

Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. ↗
Sports medicine (Auckland, N.Z.) · 2026 Aug · Journal Article, Review

Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential. ↗
International journal of molecular sciences · 2025 Jan 23 · Journal Article, Review
Read available full text ↗

Potential Therapeutic Candidates for Age-Related Macular Degeneration (AMD). ↗
Cells · 2021 Sep 19 · Journal Article, Review
Read available full text ↗

Repeat this PubMed search ↗
Search additional PubMed records ↗

Risks & interactions

Recently approved mitochondria-targeting drug for Barth syndrome; human safety data are very limited, and injection-site and allergic reactions are the main concerns.

Human safety data: FDA label

Label safety data come from only 12 males with Barth syndrome in a small crossover trial and open-label extension, so rare or long-term risks are not well understood. The label has no drug interaction section.

No condition tags: its FDA label does not single out these conditions. If a condition applies to you, talk to a doctor or pharmacist first.

Who should not use it

  • People with a serious allergic reaction to elamipretide or any ingredient
  • Newborns: the product contains benzyl alcohol and is not approved for neonates

Serious risks

  • Allergic reactions, from skin rashes and cough to serious reactions needing emergency care, appearing minutes to months after starting
  • Benzyl alcohol toxicity (gasping syndrome) in newborns

Common side effects

  • injection-site reactions

Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Forzinity (elamipretide) prescribing information ↗

Safety evidence & remaining uncertainty

Injection-site reactions were common in the development program, and serious reactions have been reported. Approval in a rare mitochondrial disorder does not establish a favorable benefit-risk balance for healthy people.

Source: FDA · First treatment for Barth syndrome ↗

Regulatory status

U.S. FDA approval
Approved
Forzinity (NDA 215244, accelerated approval September 19, 2025) to improve muscle strength in patients with Barth syndrome weighing at least 30 kg. source
FDA compounding (503A bulk list)
Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source
World Anti-Doping Agency (2026)
Not on the WADA Prohibited List
Not named. It has FDA approval (2025), so S0 does not apply. source

FDA actions

  • FDA warning letter to a "research peptide" seller (Peak Performance Peptides) naming "SS-31" (elamipretide), "PT-141", tesamorelin and GLP-1 products as unapproved new drugs. (2026-08-24) source
  • FDA warning letter to a "research peptide" seller (Royal Peptides) naming "SS-31 (Elamipretide)", tesamorelin, PT-141 and GLP-1 products as unapproved new drugs. (2026-08-24) source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Clinical uses & product context

FDA granted accelerated approval in September 2025 for Barth syndrome in patients weighing at least 30 kg. Improved knee-extensor strength supported that decision; a confirmatory trial is required to establish the predicted clinical benefit.

Source: FDA · First treatment for Barth syndrome ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Why there are no prices here

This is a prescription medicine, available only with a prescription through a pharmacy. Versions sold online as "research" products are not the approved medicine, and the FDA has warned sellers of them, so PepsRadar does not list, compare or link them. See the official product information linked in References.

Mechanism & research rationale

It interacts with cardiolipin in the inner mitochondrial membrane. Barth syndrome disrupts cardiolipin biology, providing the disease-specific rationale for studying this pathway.

Source: A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. ↗

Molecular structure

Elamipretide: 2d molecular structure. The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.⤢ Enlarge 2D
2D molecular structureThe cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.PubChem · CID 11764719 ↗

Questions worth asking

  • Is the discussion about Forzinity or a different product?
  • Does the claim match the specific population studied?
  • Forzinity has a specific Barth syndrome indication; this is not approval for general longevity use.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Video & podcast discussions: members library

Frequently asked questions

Does accelerated approval mean every benefit is confirmed?

No. It can rely on a measure reasonably likely to predict benefit, with further confirmation required.

Source: FDA · First treatment for Barth syndrome ↗

Why show a trial that missed its primary endpoints?

It is part of the evidence history. The blinded phase and uncontrolled extension need separate interpretation.

Source: A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. ↗

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

PUT THE EVIDENCE IN CONTEXT

Research guides

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections

MOLECULAR ATLAS

Elamipretide

Download illustration ↓Source record ↗
Elamipretide 2d molecular structure

The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.